Clinical Studies

  • "A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate"

    Janssen Research and Development

    Find information about this study on website

  • "DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs"

    University Hospital Ulm
    The Institute of Tumor Biology is one of the TRAFO laboratories which perform CTC analyses.

    "The HER2 status in breast cancer patients may change during the course of the disease. In 30% of initially HER2-negative patients with circulating tumor cells (CTC), HER2-positive CTCs can be detected in peripheral blood samples(1). At present, it is unclear if therapy based on the HER2 status of CTC offers a clinical benefit for these patients. The DETECT III - trial compares lapatinib, as HER2-targeted therapy in combination with standard therapy versus standard therapy alone in those patients, with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. As one of the first interventional trials based on the assessment of CTC phenotypes, the DETECT III - trial aims to evaluate the efficacy of HER2-targeted therapy in patients with MBC and HER2-positive CTCs as well as the significance of CTC as an early predictive marker for treatment response."
    Quoted from website
  • "DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs)"

    University of Ulm

    "Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC."

    Quoted from website

  • "DETECT V / CHEVENDO CHemo- Versus ENDOcrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin® (Trastuzumab) and Perjeta® (Pertuzumab) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer"

    University of Ulm

    The Institute of Tumor Biology is one of the TRAFO laboratories which perform CTC analyses.

    "Especially for diseases that are not curable such as metastatic breast cancer (MBC), the maintenance of quality of life is one of the main aims of treatments. Adverse events are well-known side effects of any cytostatic treatment and impact the patients' quality of life. Therefore, new treatment options are developed that should stop or at least slow down metastatic spread of cancer without causing negative side effects in terms of high-grade adverse events. For patients with hormone-receptor positive and HER2 positive MBC the combination of HER2-targeted therapy with endocrine therapy has already been proven to be an effective and in many cases valuable alternative to the combination of HER2-targeted therapy with chemotherapy. The high relevance of HER2-neu-targeted/endocrine treatment combinations derives from the fact that potential chemotherapy-related toxicity can be avoided, which in turn positively affects quality of life.The combination of dual HER2-targeted therapy with trastuzumab and pertuzumab plus endocrine therapy might offer a better treatment option in patients with HER2 positive and hormone-receptor positive MBC. However, this combination has not been evaluated and compared to the combination of dual HER2-targeted plus chemotherapy in a prospective randomized phase III clinical trial."

    Quoted from website

  • "TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)"

    Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels


    (search by trial number "90091" at the website)

    The Institute of Tumor Biology is one of the centers which have been authorized by the EORTC ( European Organisation for Research and Treatment of Cancer ).

  • An open-label, Phase I, dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 2010112 given once daily by subcutaneous administration or by continuous intrvenous infusion, in subjects with castration resistant prostate cancer”, BAYER study no 15590, with EudraCT Nr. 2012-000691-42

    Bayer Pharma